531506-44-2

Basic information

• Product Name: 7-[(2-trimethylsilyl)ethoxymethyl]-8-[4-{[3-(4-chlorophenyl)(1,2,4-oxadiazol-5-yl)]methoxy}phenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione
• Synonyms: 7-[(2-trimethylsilyl)ethoxymethyl]-8-[4-{[3-(4-chlorophenyl)(1,2,4-oxadiazol-5-yl)]methoxy}phenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione
• CAS NO: 531506-44-2
• Molecular Weight: 651.237
• Mol File: 531506-44-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 7-[(2-trimethylsilyl)ethoxymethyl]-8-[4-{[3-(4-chlorophenyl)(1,2,4-oxadiazol-5-yl)]methoxy}phenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[(2-trimethylsilyl)ethoxymethyl]-8-[4-{[3-(4-chlorophenyl)(1,2,4-oxadiazol-5-yl)]methoxy}phenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione(531506-44-2)
• EPA Substance Registry System: 7-[(2-trimethylsilyl)ethoxymethyl]-8-[4-{[3-(4-chlorophenyl)(1,2,4-oxadiazol-5-yl)]methoxy}phenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione(531506-44-2)

Safety Data

• Hazardous Substances Data: 531506-44-2(Hazardous Substances Data)

Upstream product

• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 531506-42-0 7-[(2-trimethylsilyl)ethoxymethyl]-8-[4-(phenylmethoxy)phenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione 
• 531506-41-9 8-[4-(phenylmethoxy)phenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione 
• 93048-83-0 (Z)-N'-(2-chloroacetoxy)-4-chlorobenzimidamide 
• 5033-28-3 4-chloro-N'-hydroxybenzimidamide 
• 81250-34-2 1,3-dipropyl-5,6-diaminouracil 
• 57238-75-2 5-(chloromethyl)-3-(4-chlorophenyl)-1,2,4-oxadiazole 
• 531506-43-1 7-[(2-trimethylsilyl)ethoxymethyl]-8-[4-hydroxyphenyl]-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione 

Relevant articles and documents

A2B adenosine receptor antagonists

Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

A2B adenosine receptor antagonists

Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS

Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.